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Antibodies against HLA and non-HLA are associated with transplantation outcome. 
Recently, pretransplant serum IgG antibody levels against apoptotic cells were found 
to correlate with kidney allograft loss. We investigated the presence of these antibodies 
in lung transplantation (LTx) patients and evaluated the correlation of pre-LTx serum 
levels of IgG antibodies against apoptotic cells with LTx outcome. These cells included 
donor lung endothelial cells (ECs) obtained from lung perfusion fluid collected during LTx 
procedure. Cells were isolated, expanded in vitro, and analyzed as targets for antiapop-
totic cell reactivity. Cultured cells exhibited EC morphology and were CD31+, CD13+, 
and vWF+. End-stage lung disease patients showed elevated serum IgG levels against 
apoptotic lung EC (p = 0.0018) compared to healthy controls. Interestingly, the levels 
of circulating antibodies directed against either apoptotic Jurkat cells or apoptotic lung 
ECs did not correlate, suggesting a target cell specificity. We observed no correlation 
between chronic or acute rejection and pre-LTx serum levels of antiapoptotic antibodies. 
Also, these levels did not differ between matched patients developing chronic rejection 
or not during follow-up or at the time of diagnosis, as they remained as high as prior to 
transplantation. Thus, circulating levels of antiapoptotic cell antibodies are elevated in 
end-stage lung disease patients, but our data do not correlate with outcome after LTx.
Keywords: lung transplantation, chronic lung allograft dysfunction, antibodies, apoptotic cells, lung endothelial 
cells
inTrODUcTiOn
Chronic lung allograft dysfunction (CLAD) is the main complication after lung transplantation (LTx). 
In 2014, the nomenclature for chronic rejection after LTx has been revised, and CLAD is divided in 
two different clinical phenotypes, an obstructive form, or bronchiolitis obliterans syndrome (BOS), 
and a restrictive from, or restrictive allograft syndrome (1). Currently, BOS is the dominant type of 
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CLAD. According to recent reports, the worldwide 5-year BOS 
free survival rate is 50%, and mean survival post-LTx is around 
10 years (2).
The pathogenesis of BOS following LTx is a multifactorial pro-
cess. Risk factors for BOS include viral infections, primary graft 
dysfunction, lymphocytic bronchiolitis, air pollution, genetic 
factors, and episodes of acute rejection (AR) (3, 4). Also, the 
development of donor-specific antibodies and de novo autoan-
tibodies may contribute to the development of BOS, though 
their role is not fully understood. Some studies have underlined 
the importance of alloimmune reactions against the transplant, 
particularly donor-specific HLA antibodies on transplantation 
outcome (5, 6), although their exact role is debated (7). In addi-
tion to alloimmunity, autoimmunity, especially in the form of 
non-HLA-specific autoantibodies against collagen type V and 
k-alpha-tubulin, are thought to contribute to an increased risk 
of BOS development (8, 9). Thus, humoral immunity against 
the transplant may be important in BOS pathogenesis and pro-
gression. Recently, circulating cell death biomarkers are found 
to be predictive for survival in human LTx, demonstrating the 
potential importance of the role of apoptosis in complications 
after LTx (10).
A major limiting factor in kidney transplantation is pretrans-
plant allosensitization, due to blood transfusions, pregnancies, or 
previous allografts (11). In line with observations in LTx, also 
preexisting non-HLA antibodies have been associated with an 
increased risk of rejection. For example, in kidney transplanta-
tion, preexisting anti-angiotensin type 1 receptor antibodies 
and anti endothelin-1 type A receptor antibodies constitute an 
independent risk factor for graft loss (12, 13). Also, vimentin, 
an intra-endothelial cell (EC) protein that can be exposed to 
the immune system after EC damage and can act as a target for 
antibody formation (14). Interestingly, Gao et  al. have shown 
that pretransplant antibodies against apoptotic Jurkat T  cells 
predict antibody-mediated rejection and graft failure of kidney 
transplants (15). The antigens of antiapoptotic antibodies have 
been partly elucidated. Polyreactive antibodies against apoptotic 
Jurkat T cells may react with phospholipids, phosphatidylserine, 
and lysophosphatidylcholine, which during apoptosis become 
exposed on the cell-membrane upon membrane flip-flop (16, 17).
Antibodies against apoptotic cells have also been detected in 
systemic autoimmune diseases, such as lupus. Indeed, apoptotic 
cells are considered as far better substrates for autoantibody 
binding than viable cells (18). Apoptotic bodies display at their 
cell surface nuclear materials including DNA, chromatin, and 
ribonucleoproteins. These autoantigens are then accessible 
to autoantibodies (19). Lastly, it is widely accepted that DNA 
becomes accessible very early on apoptotic cells, even before 
phosphatidylserine (20).
Given the similarities in pathogenic mechanisms induced by 
graft-reactive antibodies in kidney and LTx, we hypothesized 
that these antibodies against apoptotic targets preexisting or 
induced upon transplantation may correlate with outcome fol-
lowing LTx. To test this hypothesis we evaluated the presence of 
circulating antibodies against apoptotic Jurkat cells (anti-AJC) 
in a cohort of LTx patients and assessed their correlation to 
outcome. Since ECs are the primary cells encountered by the 
recipient’s immune system, we also assessed the role of antibod-
ies directed against apoptotic primary lung ECs (anti-AEC) in 
this respect. The advantage of using primary apoptotic lung 
ECs is to detect lung EC-specific antibodies. These cells were 
obtained from the donor during transplantation procedure. 
Our results indicate that antibodies against both apoptotic EC 
and Jurkat cells are present in patient serum prior to trans-
plantation, but that these antibody levels do not correlate with 
transplantation outcome.
PaTienTs anD MeThODs
Patients and sampling
We included LTx patients who underwent LTx within our center 
between September 2003 and November 2012, and of whom 
pretransplantation serum was available. Prior to transplantation, 
patients were assessed for transplant eligibility via classical cross-
match testing. Pretransplant HLA antibodies were measured 
via the LABScan 100 flow analyzer (One Lambda, CA, USA) 
or ELISA (LAT, One Lambda), as described previously (7). All 
patients were treated with standardized immunosuppressive 
regime consisting of tacrolimus, basiliximab, prednisolone, and 
mofetil mycophenolate. Patients depicted as being at risk for 
CMV or EBV reactivation (defined as a CMV−/EBV− patients 
receiving a graft from a CMV+/EBV+ donor) were prophylacti-
cally treated with valganciclovir up until 6  months after trans-
plantation. Informed consent in accordance with the Declaration 
of Helsinki was obtained from all the patients, and this study 
was approved by the medical ethical committee of the University 
Medical Center Utrecht (METC 06-144). All methods were 
carried out in accordance with the approved guidelines. Serum 
samples from 20 healthy controls (HC) who donated blood for 
research purposes were obtained, processed, and stored at −80°C 
until further usage.
Perfusate analysis, lung ec collection, 
and cell culturing
To reduce the risk for thromboembolic complication shortly 
after LTx (21), the grafted lungs were flushed antegradely via the 
pulmonary artery with perfadex solution. During this procedure, 
the lungs were ventilated at tidal volume and topically cooled. 
After explantation, the lungs were flushed for a second time, but 
now via the pulmonary vein, until the fluid became clear and 
upon inspection was free of blood clots. This flush fluid was col-
lected and centrifuged for 10 min at 1,800 rpm. The cell pellet was 
dissolved in phosphate-buffered saline (PBS) (Sigma-Aldrich, 
St. Louis, MO, USA) and subsequently loaded on Ficoll-Paque 
(GE Healthcare, Milwaukee, WI, USA) for cell separation. The 
cells were isolated from the interphase, put in aliquots of 1 ml 
in RPMI-1640 (Gibco, Waltham, MA, USA) supplemented with 
DMSO (Sigma-Aldrich) and 20% v/v fetal bovine serum (FBS) 
(Bodinco, Alkmaar, The Netherlands), and stored in liquid nitro-
gen until further processing.
Both whole perfusate and frozen cell aliquots were inspected 
for the presence of lung EC via FACS analysis using a FACSCanto 
and FACSDiva software (BD Biosciences, Durham, NC, USA) 
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and FlowJo v.10 (FlowJo, LLC, Ashland, OR, USA). Either whole 
perfusate cell samples or thawed frozen cell aliquots were stained 
with a combination of CD45-PO (Thermo Fisher Scientific, 
Rockford, IL, USA), CD31-FITC (BD Biosciences), CD13-PE 
(BD Biosciences), CD90-BV421 (BioLegend, San Diego, CA, 
USA), VEGFR-2-AF647 (BD Pharmingen), or respective iso-
types (Biolegend and R&D Systems, Minneapolis, MN, USA). 
Intracellular staining for Von Willebrand factor (vWF) was 
conducted using vWF-APC (R&D systems) and Intrastain kit 
(DAKO, Glostrup, Denmark).
For cell culturing, frozen cell samples were thawed at 37°C, 
washed with RPMI-1640 20% FBS, centrifuged for 10  min at 
1,800  rpm, and the pellet was dissolved in EC-specific growth 
medium (EBM-2, Lonza, Basel, Switzerland) and additives for 
vascular EC (EGM-2 SingleQuots, Lonza). Cells were cultured 
in gelatin (Sigma-Aldrich) pre-coated nunclon T-25 culture 
flasks (Sigma-Aldrich) in EBM-2 supplemented with primocin 
(Invivogen, San Diego, CA, USA) until confluency. Confluent 
flasks were treated with accutase (BD Biosciences), and cells were 
subcultured (50,000 per flask) in nunclon T-75 culture flasks. 
Cell morphology was assessed via light microscopy (Leica DM 
IL, Leica Microsystems, Wetzlar, Germany), and cell numbers 
analyzed via Bürker–Türk cell counting chambers (Laboroptik 
Ltd., Lancing, UK).
Jurkat cells (ATCC, Manassas, VA, USA) were cultured in 
T-75 culture flasks in RPMI-1640 10% FCS supplemented with 
1% penicillin/streptomycin (Thermo Fisher Scientific) and sub-
cultured 1:6 twice a week.
igg Purification
IgG was purified from frozen serum samples using Magne 
Protein G Beads (Promega, Madison, WI, USA) according to 
manufacturer’s instructions. Briefly, 50  μl beads were incu-
bated with 50  μl pre-centrifuged thawed serum samples for 
30–60  min at room temperature while shaking. Supernatant 
was removed via magnetic separation of the beads, which were 
subsequently washed multiple times. Purified IgG was eluted 
from the beads, and the purified IgG quality and concentration 
was obtained using the NanoDrop® ND-1000 system (Thermo 
Fisher Scientific). Purified IgG fractions were stored at 4°C until 
further usage.
antibodies against apoptotic Jurkat and 
Primary lung ecs
Anti-AJC and anti-AEC antibodies were assessed via flow cytom-
etry. Jurkat cells were co-incubated with 1 μl of 1 μM staurosporine 
(Sigma-Aldrich) O/N at 37°C to induce apoptosis. Cells were cen-
trifuged for 5 min at 1,800 rpm, the supernatant discarded, and 
the cell pellet was dissolved in 5 ml culture medium. One-hundred 
microliters of cell suspension were added to a 96-well round bot-
tom plate (Sigma-Aldrich), centrifuged (5 min, 1,500 rpm), and 
subsequently were incubated with 60 μl purified IgG (diluted 1:2 
in PBS) for 30  min at 37°C. Each well was washed twice with 
150 μl PBS and centrifuged (5 min, 1,500 rpm). The supernatant 
was discarded, and the cells were incubated with mouse anti 
human IgG PE (BioLegend), diluted 1:12.5 in PBS for 30 min at 
4°C. Cells were washed once with 150 μl PBS and once with 150 μl 
annexin V binding buffer (1 l H2O + 10 mM Hepes + 140 mM 
NaCL + 2.5 mM CaCl2⋅2H2O; pH 7.4). Cells were centrifuged, the 
supernatant discarded, and100 μl binding buffer supplemented 
with 4 μl 7AAD (BD Pharmingen, San Diego, CA, USA) and 
annexin V FITC (ITK Diagnostics, Uithoorn, The Netherlands), 
diluted 1:2, was added followed by 10 min incubation at room 
temperature and fluorescence measurement.
In order to induce apoptosis, lung EC were subjected to serum 
starvation for 48–72 h at 37°C, culturing with staurosporine O/N 
or exposed to UV light using an UV stratalinker (Stratagene, Santa 
Clara, CA, USA). Serum starvation yielded the largest amount of 
apoptotic EC (35–40%). After serum starvation, cells were washed 
with PBS and detached with 4 ml accutase for 5 min at 37°C. Cell 
detachment was determined via light microscopy. Six milliliters 
of culture medium was added to the culture flask and centrifuged 
for 5 min at 1,500 rpm. The supernatant was discarded and the cell 
pellet dissolved in PBS. One hundred microliters cell suspension/
well (V bottom 96-well plate, Sigma-Aldrich) and incubated with 
60 μl purified IgG (mean concentration 548 ± 154 μg/ml), diluted 
1:2 in PBS for 30 min at 37°C. Subsequent antibody incubations 
were identical to the previous described Jurkat protocol. All 
measurements for either Jurkat or primary EC were conducted on 
the same day. To determine the intra- and inter-assay variation, 
cells were seeded in duplicate and identical sera measured on 
multiple days. The inter- and intra-assay variability for this assay 
were 18 and 4.1%, respectively.
statistics
The D’Agostino and Pearson omnibus normality test was used 
to test the data for Gaussian distribution. Differences in not-
normally distributed data were analyzed via the Mann–Whitney 
test, whereas Student’s t-tests were used to asses differences in 
normally distributed data. Correlation analyses on non-normally 
distributed data were performed with the Spearman’s rank cor-
relation coefficient. Statistical analyses were performed using 
GraphPad Prism version 6.02 (GraphPad Software Inc., San 
Diego, CA, USA) and SPSS version 20 (IBM Corp., Armonk, 
NY, USA). Information on statistical testing and graph display 
is depicted in the respective figure legend. A p-value <0.05 was 
considered to be statistically significant.
resUlTs
Patients
A total of 80 patients who underwent LTx within our center 
between September 2003 and November 2012, and of whom 
pretransplantation serum was available, were included in this 
study. Twenty-nine of these patients were diagnosed with BOS 
based upon ISHLT criteria (22), and in our total cohort 22 
patients died during follow-up, of whom 9 were diagnosed with 
BOS. Seventeen patients developed one or more episodes of 
AR, diagnosed, since biopsies were unavailable, as a spontane-
ous decline of FEV1 reversible via steroid-pulse treatment. One 
patient was positive for anti-HLA antibodies directed at DQ4, 
whereas none of the other patients presented with pretransplant 
TaBle 1 | Patient cohort (n = 80).
Parameters Values
Gender, n (%)
Male 39 (48.8%)
Female 41 (51.2%)
Age in year (mean ± SD) 44.4 ± 13.2
Follow-up in months (mean ± SD) 78.7 ± 36.7
End-stage lung disease, n (%)
COPD 37 (46.2%)
CF 27 (33.8%)
ILD 16 (20.0%)
BOS, n (%) 29 (36.3%)
Months post-LTx BOS (mean, 
min–max)
41 (5–124)
Deceased, n (%) 22 (27.5%)
Months post-LTx deceased 
(mean, min–max)
40 (8–98)
AR, n (%) 17 (21.3%)
COPD, chronic obstructive pulmonary disease; CF, cystic fibrosis; ILD, interstitial 
lung disease; BOS, bronchiolitis obliterans syndrome; AR, acute rejection; LTx, lung 
transplantation.
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anti-HLA antibodies, as described previously (7). Further clinical 
and demographic parameters are depicted in Table 1.
lung ec culturing and characterization
First, we analyzed perfusate samples from six patients for the 
presence of vascular EC as determined by FACS. Vascular lung 
EC were identified as being CD45−/VEGFR-2+/CD13+ and 
confirmed by intracellular staining of vWF. The percentage 
of EC in each perfusate was assessed by analyzing 1,000,000 
cells. This percentage ranged from 0.0002 to 0.0256% (see 
Figure 1A). For further analysis of ECs, cells in the perfusate 
were first expanded in primary cell cultures. Individual ECs 
were observed within the first week after initial cell seeding. 
Cell numbers sufficient for subculturing or cell marker analysis 
were reached in 2–5 weeks (Figure 1B). ECs were cultured for 
a maximum of nine passages.
Endothelial cells were characterized via cell morphology, cell 
surface, and intracellular markers. Cells in culture presented 
typical EC morphologic characteristics. Cell density per passage 
differed. Furthermore, monolayers were observed in later culture 
passages, and cell morphology remained constant during cultur-
ing (Figure 1C, passages 1–4). ECs were non-lymphoid (CD45−). 
Cells could be cultured without any morphological indications of 
cell death until passage nine. FACS analysis showed that cultured 
EC expressed both EC-specific markers CD13 and CD31 on their 
cell surface. Furthermore, intracellular staining revealed these 
cells to be positive for vWF (Figure 1D).
end-stage lung Disease Patients exhibit 
increased circulating levels of antibodies 
against apoptotic cells
As these cells have been used frequently as a source of apoptotic 
cells, we first tested the presence of antibodies against apoptotic 
Jurkat cells. Apoptosis was induced as described in the Section 
“Materials and Methods.” Overall apoptosis rates in Jurkat cells 
were around 60–70% of total cell numbers. Higher levels of 
antibodies against apoptotic Jurkat cells were observed in LTx 
patients before transplantation as compared to HC (p < 0.001, 
Figure 2A).
Endothelial cells induced to apoptosis were analyzed with 
flow cytometry. Annexin V+/7AAD− cells were considered 
to be early apoptotic cells and Annexin V+/7AAD+ cells late 
apoptotic. Overall apoptosis rates in EC were around 20–30% 
of total cell numbers. Apoptosis induction via exposure to UV 
radiation did not result in sufficient apoptotic EC numbers 
(<5%, data not shown). Purified pre-LTx serum IgG of 80 
end-stage lung disease patients was analyzed for binding to 
apoptotic EC, from 2 different lung donors, together with serum 
IgG of 20 HC. We observed a higher IgG reactivity to apoptotic 
ECs in pre-LTx serum samples compared to HC (p = 0.0018; 
Figure 2B).
The difference between apoptotic specific IgG levels between 
end-stage lung disease patients and HCs was higher on apoptotic 
Jurkat cells. We did not observe differences in IgG antibody 
reactivity to apoptotic targets when early and late apoptotic ECs 
or Jurkat cells were differentiated. Stratification of serum IgG 
titers per end-stage lung disease, clustered as COPD, CF, and 
ILD did not show any significant differences. Also, no significant 
differences were observed when age, autoimmune disease, or 
anti-HLA antibodies were taken into account. Furthermore, 
we observed no correlation between anti-AJC and anti-AEC 
(Figure  2C). A heat-map representation of the individually 
observed mean fluorescent intensity (MFI) values is depicted in 
Figure 2D.
Pre-lTx serum igg reactivity to apoptotic 
Targets Does not correlate with clinical 
Outcome after lTx
We analyzed the relation of pre-LTx levels of anti-AJC and 
anti-AEC and outcome after LTx. First, we stratified patients by 
development of BOS during follow-up. Twenty-nine patients 
were diagnosed with BOS. No differences were observed between 
serum IgG levels of anti-AEC or anti-AJC in BOS+ and BOS− 
patients (Figures 3A,B, respectively). Also, these pre-LTx levels 
did not correlate to time to BOS diagnosis or time to death (data 
not shown).
Second, we investigated the predictive value of pre-LTx serum 
IgG levels on the incidence of AR post-LTx. In total, 17 patients 
were diagnosed with one or more episodes of AR. We observed 
no significant differences between serum levels of anti-AEC or 
anti-AJC in LTx patients with or without AR (Figures  3C,D, 
respectively).
serum igg reactivity during BOs 
Development
Since we did not observe any predictive value concerning pre-
transplant levels of serum IgG reactivity to apoptotic cells, we 
investigated levels of these antibodies at the time of BOS diag-
nosis. We isolated serum IgG from serum samples obtained from 
10 patients within a month that BOS was diagnosed. In parallel, 
we selected serum samples from 10 patients who did not develop 
BOS and were matched for gender, age, primary lung disease, 
FigUre 1 | endothelial cell (ec) culture characteristics. (a) Schematic representation of the numbers of EC per 1,000,000 cells in a single lung perfusate 
sample. Cell numbers were quantified via flow cytometry. (B) Overview of primary lung EC cultures. ECs from different donor perfusate samples were cultured in 
EBM-2 EC-specific medium. Five different perfusate samples were seeded in gelatin-coated culture flasks, and cell numbers were assessed on different culture days, 
when cell density was high enough to further passage the cell cultures. Large differences were observed in cell growth rates between individual cell cultures. (c) Light 
microscopy images of different primary EC cultures. Typical EC morphology could be observed, as well as clustering of EC at higher cell densities. Passage 1, 100×, 
passage 2, 400×, passage 3, 100×, passage 4, 100×. (D) EC characterization via flow cytometry. Cell cultures were detached using accutase cell detachment 
solution. ECs were gated as large cells based on forward/sideward scatter. Gated cells were from the non-lymphoid lineage (CD45−) and expressed both CD31 and 
CD13, characteristic for ECs. Furthermore, intracellular staining revealed these cells to be vWF positive. Density plots were created using FlowJo analysis software.
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and month post-LTx. IgG was purified from these samples as 
described in Section “Materials and Methods.” No increase in 
IgG reactivity was observed against either apoptotic lung EC 
(Figure 4A) or apoptotic Jurkat cells (Figure 4B).
In order to gain insight into the course of IgG antibodies 
against apoptotic cells, we divided the time from transplanta-
tion to BOS diagnosis in four even time frames (quartile-based 
selection). Subsequently, we isolated IgG from serum samples 
obtained during each quartile and analyzed these samples 
for IgG reactivity. This procedure was also conducted for the 
matched BOS− patients. Overall, we observed an increased level 
of IgG antibodies against apoptotic Jurkat cells in BOS+ patient 
compared to BOS− patients during follow-up. However, this dif-
ference is not significant and does not seem to be discriminative 
at time points prior to clinical manifestations of chronic rejection 
(Figure 4C).
DiscUssiOn
The prediction and diagnosis of chronic rejection after LTx 
remains challenging. In this research, we analyzed the levels 
of antibodies against apoptotic ECs and Jurkat cells in a cohort 
FigUre 2 | end-stage lung transplantation (lTx) patients present with elevated levels of serum igg against apoptotic targets. Pre-LTx serum IgG 
reactive against both apoptotic primary endothelial cells (ECs) (a) and Jurkat cells (B) were measured and compared to healthy controls (HC). End-stage lung 
disease patients present with significant higher levels of antibodies against apoptotic EC and apoptotic Jurkat cells compared to HC (p = 0.0018 and p < 0.0001, 
respectively). The y-axis depicts the Log2 values of the measured mean fluorescent intensity (MFI). The data are represented as box and whiskers plot where the 
horizontal bar depicts the median value, the box both 25th and 75th percentiles, and the whiskers the minimum and maximum of the observed values. The data 
follow a non-Gaussian distribution, Mann–Whitney test, pre-LTx n = 80, HC n = 20. (c) No correlation was found between serum levels of antibodies directed at 
apoptotic Jurkat or apoptotic ECs. The data are normally distributed, Pearson correlation coefficient. (D) Heat-map representation of the 80 measured purified 
serum IgG samples from LTx patients and 16 HC on both Jurkat cells and 2 lung EC sources. The shades of gray represent the observed MFI according to the 
scale.
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of end-stage LTx patients. Our results indicate that end-stage 
lung disease patients have elevated levels of antiapoptotic 
antibodies against both cell types. However, these titers do 
not seem to be predictive for the clinical outcome after LTx. 
Furthermore, we describe the technique to culture primary lung 
vascular ECs from perfusate obtained during LTx procedure.
FigUre 3 | Pre-lung transplantation (lTx) igg antibodies to apoptotic cells do not correlate with clinical outcome after lTx. Pre-LTx purified IgG levels 
against apoptotic endothelial cells (a,c) and Jurkat cells (B,D) were stratified according to either bronchiolitis obliterans syndrome (BOS) diagnosis (a,B) or the 
incidence of acute rejection (AR) (c,D). Neither BOS+ nor AR+ patients presented with different purified pre-LTx IgG levels. Therefore, no correlation between IgG 
reactivity against apoptotic cells and clinical outcome after LTx was observed. The data are represented as box and whiskers plot where the horizontal bar depicts 
the median value, the box both 25th and 75th percentiles, and the whiskers the minimum and maximum of the observed values. (B) Data normally distributed, 
unpaired t-test. (a,c,D) Data not-normally distributed, Mann–Whitney test. BOS+ n = 29, BOS− n = 51, AR+ n = 17, AR− n = 63.
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Antibodies against apoptotic targets have been identified in 
previous studies, with Jurkat cells as model for cellular apoptosis 
(16, 23, 24). In our initial observations on antibodies against 
apoptotic Jurkat cell we observed Log2 IgG reactivity levels in 
concordance to the results published by Gao et al. Furthermore, 
the levels of antibodies directed at apoptotic ECs were also within 
this range.
The primary EC culturing method presented in this paper 
is novel and has potential implications for LTx research. Donor 
lung ECs are the first cells recognized by the recipient’s immune 
cells, initiating, among others, direct allorecognition via MHC 
antigens, which are expressed on these cells (25). Also, ECs are 
suggested to play a major role in the pathogenesis of chronic 
rejection, due to the secretion of pro-inflammatory cytokines 
upon activation (26, 27). Therefore, research has been conducted 
into the interplay of transplantation patient’s immune cells or 
serum components, serially collected post-transplantation and 
EC lines, such as human umbilical vein EC (28, 29). Since our 
method allows to culture these ECs directly from the donor, this 
in vitro model enables us to investigate the interface of immune 
activation between donor ECs and patient PBMCs in a biologically 
more relevant way. This opens new perspectives for LTx research.
Pretransplant antibodies against apoptotic Jurkat cells in 
kidney transplantation patients have been found to correlate 
with late kidney allograft loss (15). We did not confirm these 
observations in our cohort of LTx patients. Neither pre-LTx 
antiapoptotic IgG serum levels directed against apoptotic ECs 
nor Jurkat cells correlated with the incidence of acute or chronic 
rejection. Furthermore, levels of these antibodies during follow-
up after LTx were not discriminative for differences in clinical 
outcome. We also distinguished between early and late apoptotic 
cells, but no differences could be observed regarding end-stage 
lung disease or outcome after LTx. These results suggest differ-
ences in the contribution of these antibodies on the underlying 
pathological process in the development of rejection in both 
kidney and LTx.
Except for one patient, no antibodies against HLA were found 
in the serum of our cohort, which has been published previously 
(7). This is in contrast to kidney transplantation cohorts, where 
highly immunized patients are often observed (15). This low 
immunization grade can be explained by the fact that no retrans-
plantation patients are present in our cohort. Also, a large part 
(34%) of our cohort consists of young female CF patients who 
have not been through pregnancy. Since no anti-HLA antibod-
ies are present, we exclude the possibility that the observed IgG 
reactivity is directed against either Jurkat or donor allogeneic 
HLA antigens in both our apoptotic cell death models.
Synergistic effects of anti-HLA antibodies and non-HLA 
antibodies on graft survival have been described for different 
non-HLA antibodies, including antibodies against apoptotic 
FigUre 4 | Purified serum igg against apoptotic cells at bronchiolitis obliterans syndrome (BOs) diagnosis and progress during transplantation 
follow-up. Levels of purified serum IgG, obtained at BOS diagnosis, were analyzed in a cohort of 10 BOS+ patients and 10 BOS− patients matched for age, 
gender, month after transplantation, and primary lung disease. No differences between these two groups were observed using either apoptotic endothelial cells 
(a) or Jurkat cells (B). Data normally distributed, unpaired t-test, BOS+ n = 10, BOS− n = 10 (c). In order to gain insight into the course of IgG antibodies against 
apoptotic targets during follow-up after lung transplantation we used a quartile-based selection method. For this end, we divided the time from transplantation to the 
moment of BOS diagnosis in four equal quartiles and purified IgG from serum taken at each quartile. Parallel to 10 BOS+ patients, we analyzed 10 matched 
BOS− patients, mentioned above, via this approach. BOS+ patients present with slightly elevated IgG levels specific for apoptotic targets, although this difference is 
not significant. Each dot represents the mean ± SEM of 10 analyzed individuals. Two-way ANOVA on Log2 transformed mean fluorescent intensity (MFI), with BOS 
as independent source of variation.
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cells, in kidney transplantation (30, 31). The impact of anti-HLA 
antibodies on LTx outcome is less well established as compared 
to kidney transplantation. Hence, our findings may imply that 
observations on the impact of various antibodies on graft sur-
vival in kidney transplantation cannot be simply extrapolated 
to LTx. For example, immunosuppressive regimens or tissue-
specificity of involved antiapoptotic antibodies, hamper such 
extrapolation (32, 33).
Clearance of apoptotic cells is facilitated by various immune-
involved processes, including IgM natural antibodies, speculated 
to be specific for lysophospholipids (14, 24). Furthermore, it is 
postulated that, in the autoimmune disease systemic lupus ery-
thematosus, class-switching of the natural IgM antibodies to the 
IgG isotype occurs (34). Whereas their epitopes are unknown, 
antibodies of the IgG isotype against apoptotic Jurkat cells are 
believed to be polyreactive against multiple epitopes on the mem-
branes of apoptotic cells, including phospholipids (17). The level 
of apoptosis induction differed between ECs (35%) and Jurkat 
cells (60–75%), and differences in sensitivity to apoptosis induc-
tion has been described previously (35). This difference could 
affect the absolute number of detected antiapoptotic antibodies. 
Interestingly, we found no correlation between the levels of anti-
bodies reactive against apoptotic Jurkat cells or apoptotic lung 
ECs, which could be contributed to a different epitope specificity 
of these IgG antibodies. The nature of these epitopes, in particular 
ECs, remains speculative and therefore in-depth antibody char-
acterization and research on subsequent effector mechanisms is 
expedient.
The importance of antibodies in end-stage lung diseases has 
been stressed by previous research from our group and others. 
Autoantibodies have been identified in end-stage CF patients (35, 
36), and the levels of various autoantibodies are associated with 
disease progression (37). Autoantibodies, including antibodies 
against various tissue epitopes, are present in COPD patients and 
relate to lung function (38, 39), Indeed, indications for autoim-
munity have been observed in specific subgroups of ILD patients 
(40, 41).
To our knowledge, we are the first to report on antibodies 
against apoptotic cells in end-stage lung disease patients. We 
speculate that extensive tissue damage in the diseased lungs of 
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LTx patients has led to the presentation of novel antigens, which 
have triggered antibody formation. In conclusion, preexisting 
antibodies against apoptotic lung ECs or apoptotic Jurkat cells 
do not correlate with outcome after LTx, which is in marked 
contrast to observations in other transplantation settings. Hence, 
one should be careful to extrapolate observations on immune 
mechanisms from one transplantation setting to another.
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